RhoA Antibody (1A11-4G10)

Immunocytochemistry/ Immunofluorescence: RhoA Antibody (1A11-4G10) [NBP2-22528]

Immunocytochemistry/Immunofluorescence: RhoA Antibody (1A11-4G10) [NBP2-22528] - Analysis of RhoA/B/C (green) in NIH3T3 cells. Formalin fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 10 minutes at room temperature and blocked with 1% BSA/TBST for 15 minutes at room temperature. Cells were probed with a RhoA/B/C monoclonal antibody at a dilution of 1:100 for at least 1 hour at room temperature, washed with PBS, and incubated with DyLight 488-conjugated goat-anti-mouse IgG secondary antibody at a dilution of 1:400 for 30 minutes at room temperature. Nuclei (blue) were stained with Hoechst 33342 dye.

Immunocytochemistry/ Immunofluorescence: RhoA Antibody (1A11-4G10) [NBP2-22528]

Immunocytochemistry/Immunofluorescence: RhoA Antibody (1A11-4G10) [NBP2-22528] - Analysis of Rho A/B/C (green) showing staining in the in the cytoplasm of NIH-3T3 cells (right) compared to a negative control without primary antibody (left).

Immunohistochemistry-Paraffin: RhoA Antibody (1A11-4G10) [NBP2-22528]

Immunohistochemistry-Paraffin: RhoA Antibody (1A11-4G10) [NBP2-22528] - Analysis of showing staining in the cytoplasm of mouse breast tissue (right) compared with a negative control without primary antibody (left).

Immunohistochemistry-Paraffin: RhoA Antibody (1A11-4G10) [NBP2-22528]

Immunohistochemistry-Paraffin: RhoA Antibody (1A11-4G10) [NBP2-22528] - Analysis showing staining in the cytoplasm of human prostate carcinoma (right) compared with a negative control without primary antibody (left).

Immunoprecipitation: RhoA Antibody (1A11-4G10) [NBP2-22528]

Immunoprecipitation: RhoA Antibody (1A11-4G10) [NBP2-22528] - Analysis of RhoA/B/C was performed on HeLa cells. Antigen-antibody complexes were formed by incubating 750 ug of HeLa cell lysate with 2 ug of a RhoA/B/C monoclonal antibody overnight on a rocking platform at 4C. The immune complexes were captured on 50 ul Protein A/G Plus Agarose, washed extensively, and eluted with 5X Lane Marker Reducing Sample Buffer. Eluted sample (right lane) and 25 ug of HeLa cell lysate (left lane) were resolved on a 4-20% Tris-HCl polyacrylamide gel, transferred to a PVDF membrane, and blocked with 5% BSA/TBS-0.1%Tween for at least 1 hour. The membrane was probed with a Rho A/B/C monoclonal antibody at a dilution of 1:1000 overnight rotating at 4C, washed in TBST, and probed with Clean-blot IP Detection Reagent at a dilution of 1:2500 for at least 1 hour.

Western Blot: RhoA Antibody (1A11-4G10) [NBP2-22528] -

The cellular signaling pathway involved in regulating intracellular Ca2+ oscillation in a rat model of OHD-induced DHIC. The expressions of signaling-pathway-related proteins, including Gq/11, Gq/12, Gq/13, RhoA, and RhoK, were quantified by Western blots (A). In the OVX group, the protein expression levels were reduced compared with the sham group. The LiESWT treatment significantly promoted the protein levels in the OVX + SW4 group and the OVX + SW8 group in comparison with the OVX group. DHIC, detrusor hyperactivity with impaired contractility. Data are expressed as the means +/- SD for n = 8. * p < 0.05 and ** p < 0.01 versus the sham group; # p < 0.05 and ## p < 0.01 versus the OVX group; † p < 0.05 and †† p < 0.01 versus the OVX + SW4 group (B). Image collected and cropped by CiteAb from the following open publication (https://www.mdpi.com/1422-0067/25/9/4927), licensed under a CC-BY license. Not internally tested by Novus Biologicals.